| Identification | Back Directory | [Name]
H-D-GLU(TRP-OH)-OH | [CAS]
229305-39-9 | [Synonyms]
GLU-TRP
GolotiMod
GAMMA-GLU-TRP
Unii-637C487Y09
H-g-D-Glu-Trp-OH
H-GLU(TRP-OH)-OH
gamma-D-Glu-L-Trp
H-D-GLU(TRP-OH)-OH
H-GAMMA-GLU-TRP-OH
H-GAMMA-D-GLU-TRP-OH
gammaDglutamylLtryptophan
L-Tryptophan, D-γ-glutamyl-
GOLOTIMOD (UNII-637C487Y09)
H-g-D-Glu-Trp-OH, GolotiMod, BestiM
SCV 07; SCV-07; SCV07; GAMMADGLUTAMYLLTRYPTOPHAN
(2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid | [Molecular Formula]
C16H19N3O5 | [MDL Number]
MFCD00057875 | [MOL File]
229305-39-9.mol | [Molecular Weight]
333.34 |
| Chemical Properties | Back Directory | [Boiling point ]
737.3±60.0 °C(Predicted) | [density ]
1.428±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
2.22±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)[1][2][3]. | [Definition]
ChEBI:Golotimod is a dipeptide. | [in vivo]
Golotimod (SCV-07) (oral gavage or subcutaneous injection, 100 μg/kg, 5 days) reduces experimental recurrent genital HSV-2 disease by oral administration, more importantly, oral SCV07 after fasting shows a greater reduction in incidence and severity than SCV-07 without fasting in female hartley guinea pigs[1].
Golotimod (SCV-07) (subcutaneous injection, once or twice a day from days 1 to 20, 100 μg/kg) can reduce the severity and duration of acute and split radiation-induced oral mucositis (OM) and short the duration of ulcerative OM in male LVG golden Syrian Hamsters[3].
| Animal Model: | Female Hartley guinea pigs (250-300 g) infected HSV-2[1] | | Dosage: | 100 μg/kg | | Administration: | Oral gavage or subcutaneous injection; 5 days | | Result: | Reduced incidence of lesions from 55% (one week before treatment) to only 18% by oral administration, and showed no significant reduction in disease by subcutaneous injection of SCV-07. |
| Animal Model: | Male LVG golden Syrian Hamsters weighing approximately 80 g with radiation-induced mucositis[3] | | Dosage: | 10, 100 μg/kg or 1 mg/kg | | Administration: | Subcutaneous injection; once or twice a day from days 1 to 20 | | Result: | Showed a peak mucositis of 3.0 on day 18 in the control group compared to only 2.2 in the test group, and the mucositis score in the SCV-07 treated hamsters was only 6.3% compared to 28.1% in the control group at dose of 100 μg/kg.
Significantly decreased the severity and duration of oral mucositis (OM) at dose of 10 μg/kg, 100 μg/kg or 1 mg/kg.
|
| [IC 50]
STAT3 | [storage]
Store at -20°C | [References]
[1] Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Int J Antimicrob Agents. 2008 Sep;32(3):262-6. DOI:10.1016/j.ijantimicag.2008.04.010
[2] Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016 May;56:84-92. DOI:10.1016/j.oraloncology.2015.11.022
[3] Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). Oral Dis. 2010 Oct;16(7):655-60. DOI:10.1111/j.1601-0825.2010.01671.x |
|
|